Endonovo Therapeutics, Inc. (ENDV) Stock

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Endonovo Therapeutics, Inc. (ENDV) stock trades at $0.00 with a market capitalization of $31875. The stock is valued at a price-to-earnings (P/E) ratio of 1.00, a negative price-to-book of -0.01, reflecting negative shareholders' equity, price-to-sales of 0.71.

On profitability, Endonovo Therapeutics, Inc. generates a return on equity (ROE) of 6.90% (not meaningful, as shareholders' equity is negative), return on capital employed of 3.38%.

Official website: www.endonovo.com